Fulcrum Therapeutics (NASDAQ:FULC) Now Covered by Truist Financial

Truist Financial initiated coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research report sent to investors on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $14.00 target price on the stock.

A number of other equities research analysts have also weighed in on the company. Leerink Partners set a $20.00 price objective on Fulcrum Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. HC Wainwright boosted their price target on Fulcrum Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Monday. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective (up previously from $12.50) on shares of Fulcrum Therapeutics in a report on Thursday, October 30th. Royal Bank Of Canada lifted their target price on shares of Fulcrum Therapeutics from $5.00 to $7.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.17.

Fulcrum Therapeutics Price Performance

FULC stock opened at $11.74 on Monday. The company has a 50 day simple moving average of $8.96 and a 200 day simple moving average of $7.63. The stock has a market cap of $635.37 million, a price-to-earnings ratio of -9.95 and a beta of 3.02. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $12.19.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). On average, equities research analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total transaction of $165,450.00. Following the completion of the transaction, the director owned 484,864 shares in the company, valued at approximately $5,348,049.92. This trade represents a 3.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds have recently bought and sold shares of FULC. Jump Financial LLC acquired a new position in Fulcrum Therapeutics in the first quarter valued at $30,000. Brooklyn Investment Group raised its position in shares of Fulcrum Therapeutics by 209.7% in the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock worth $35,000 after acquiring an additional 8,254 shares in the last quarter. Quarry LP acquired a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at about $35,000. Virtu Financial LLC bought a new stake in shares of Fulcrum Therapeutics during the 1st quarter valued at about $39,000. Finally, Russell Investments Group Ltd. grew its stake in Fulcrum Therapeutics by 4,209.3% during the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after purchasing an additional 9,092 shares during the period. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.